Skip to content
HomeLatest newsGlassdoor names Johnson & Johnson’s Alex Gorsky a 2018 top CEO
FINAL LEDE- A Look Back on Our Work in 2019- Alex gorsky dyir digital year in review

Glassdoor names Johnson & Johnson’s Alex Gorsky a 2018 top CEO

The Chairman and CEO has now appeared on the Glassdoor list for five years running—all thanks to his employees.

How many people can say they love their boss? At Johnson & Johnson, a whole lot of employees can—and do.

For the fifth year in a row, Alex Gorsky, Chairman of the Board and Chief Executive Officer of Johnson & Johnson, has been named to Glassdoor’s Employees’ Choice Awards list of Top CEOs.

Glassdoor, one of the world’s largest jobs and recruiting sites, compiles its annual list of best CEOs throughout North America and parts of Europe based solely on employee reviews submitted through its platform—and 95% of staffers who reviewed Johnson & Johnson for the 2018 rankings said they approved of Gorsky’s leadership.

To help put that into perspective, 770,000 companies were reviewed, and the average CEO approval rating came in at 69%.

As the seventh Chairman and CEO since the company went public in 1944, Gorsky’s leadership has personified the values of Johnson & Johnson’s Credo—the company’s guiding mission statement, which prioritizes the needs of patients and employees alike—and has helped Johnson & Johnson solidify its position as the largest and most broadly based healthcare company in the world.

And this isn’t the only accolade the company has recently garnered under Gorsky’s direction: Johnson & Johnson also took the #1 spot on the 2018 DiversityInc Top 50 Companies for Diversity list, and was named a 2018 Fortune World’s Most Admired Company.

Congratulations to Gorsky on the recognition of his exceptional leadership.


More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.